From 1 July 2026, changes to Australia's pneumococcal vaccination program mean that some adults may be eligible for a newer pneumococcal vaccine (Capvaxive) to provide protection against more strains
Respiratory Syncytial Virus (RSV) is a common respiratory infection. From the 15th of May 2026 the RSV vaccine funding under the National Immunisation Program is expanding. If eligible, the RSV vacc
Influenza can vary in severity, and vaccination is one strategy that may reduce the risk of infection and its complications. The National Immunisation Program (NIP) provides funded vaccines for Medica